This is an old revision of this page, as edited by Jytdog (talk | contribs) at 23:55, 22 May 2018 (all bad edits. Thiel is not even an investor in the company . Inc source says ONLY that "Jason Camm, chief medical officer at Thiel Capital, who expressed interest in what the company was doing."). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 23:55, 22 May 2018 by Jytdog (talk | contribs) (all bad edits. Thiel is not even an investor in the company . Inc source says ONLY that "Jason Camm, chief medical officer at Thiel Capital, who expressed interest in what the company was doing.")(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) | This article needs more reliable medical references for verification or relies too heavily on primary sources. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed. Find sources: "Young blood transfusion" – news · newspapers · books · scholar · JSTOR (May 2018) |  |
Young blood transfusion refers to the transfusion of blood taken from a young person into an older person with the intention of having a medicinal effect beyond that of a normal blood transfusion.
There is no good evidence that "young blood" has any medicinal effect in people and all blood transfusions have risks, including blood-borne diseases. As of of 2017 evidence from two large studies showed that transfusion of blood from younger donors was either no different from, or led to worse outcomes than, blood from older donors. Research on blood transfusion outcomes has been complicated by the lack of careful characterization of the transfusion products that have been used in clinical trials; research had focused on how storage methods and duration might affect blood, but not on the differences among lots of blood themselves.
A company called Alkahest was spun out of Stanford University based on research in rodents done by scientists there; the company is collaborating with Grifols to create a blood plasma-based experimental biologic drug, which they propose to test in people with Alzheimer's.
Ambrosia is a company that sells what it calls "young blood transfusions" for $8,000 under the guise of running a clinical trial to see if such transfusions lead to changes in the blood of recipients. Peter Thiel is an investor in Ambrosia; regenerative medicine was a fad in Silicon Valley starting in the 2000s.
References
- ^ Novella, Steven (3 August 2016). "Parabiosis – The Next Snakeoil". Science-Based Medicine.
- Garraud, O (August 2017). "Younger blood from older donors: Admitting ignorance and seeking stronger data and clinical trials?". Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 56 (4): 635–636. doi:10.1016/j.transci.2017.07.002. PMID 28780993.
- Ning, S; Heddle, NM; Acker, JP (January 2018). "Exploring donor and product factors and their impact on red cell post-transfusion outcomes". Transfusion medicine reviews. 32 (1): 28–35. doi:10.1016/j.tmrv.2017.07.006. PMID 28988603.
- ^ de Magalhães, JP; Stevens, M; Thornton, D (November 2017). "The Business of Anti-Aging Science". Trends in biotechnology. 35 (11): 1062–1073. doi:10.1016/j.tibtech.2017.07.004. PMID 28778607.
- Drew, L (27 September 2017). "Neuroscience: The power of plasma". Nature. 549 (7673): S26 – S27. doi:10.1038/549S26a. PMID 28953857.
- Bercovici, Jeff (1 August 2016). "Peter Thiel Is Very, Very Interested In Young People's Blood". Inc.
- Maxmen, Amy (13 January 2017). "Questionable "Young Blood" Transfusions Offered in U.S. as Anti-Aging Remedy". MIT Technology Review.